| Date Filed | Type | Description |
| 07/14/2020 |
8-K
| Quarterly results |
| 06/12/2020 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/30/2020 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/13/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/21/2020 |
8-K
| Bankruptcy or Receivership, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officer...|
Docs:
|
"Novelion Therapeutics Confirms Commencement of Voluntary Liquidation VANCOUVER, British Columbia, January 16, 2020 – Novelion Therapeutics Inc. today announced that the implementation of the Company’ s voluntary liquidation commenced at 5:00 p.m. Pacific Time today, January 16, 2020 . As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator and charged with overseeing all aspects of the Liquidation. Concurrent with the Liquidator’ s appointment: Michael Price, previously Executive Vice President, Chief Financial Officer and sole executive officer and employee of the Company, resigned his positions, and Michael Price, Suzanne Bruhn, and Stephen Sabba resigned as directors of the Company. Shareholders and other interested parties should visit www.alvarezandmarsal.com/n..." |
|
| 01/21/2020 |
SC 13G/A
| NB Public Equity K/S reports a 9% stake in Novelion Therapeutics Inc. |
| 01/15/2020 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 01/10/2020 |
SC 13G/A
| EdgePoint Investment Group Inc. reports a 18.7% stake in NOVELION THERAPEUTICS INC. |
| 01/03/2020 |
8-K
| Quarterly results |
| 12/17/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 12/11/2019 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 11/15/2019 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 11/05/2019 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events |
| 10/08/2019 |
8-K
| Quarterly results |
| 10/08/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/03/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/03/2019 |
GN
| Novelion Therapeutics Announces Filing of Definitive Proxy Statement in Connection with Proposed Liquidation and Other Matters |
| 10/03/2019 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 10/03/2019 |
8-K
| Quarterly results |
| 10/03/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 10/02/2019 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 09/27/2019 |
SC 13D/A
| Whitefort Capital Master Fund, LP reports a 1.5% stake in Novelion Therapeutics Inc. |
| 09/27/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Departure of Directors o... |
| 09/25/2019 |
8-K
| Bankruptcy or Receivership, Completion of Acquisition or Disposition of Assets, Departure of Directors or Certain Officers; E... |
| 09/25/2019 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 09/25/2019 |
GN
| Novelion Therapeutics Announces Completion of Aegerion Transaction and Departure of Certain Directors and Officers |
| 09/20/2019 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 09/20/2019 |
SC 13D/A
| Healthcare Value Capital, LLC reports a 7.4% stake in Novelion Therapeutics Inc. |
| 09/11/2019 |
8-K
| Quarterly results |
| 09/11/2019 |
GN
| Novelion Therapeutics Announces US Court Confirmation of Aegerion Bankruptcy Case, Update on Nasdaq Delisting and Date of Annual General Meeting of Shareholders |
| 08/30/2019 |
8-K
| Other Events |
| 08/30/2019 |
GN
| Novelion Therapeutics Provides Update Regarding Delisting from Nasdaq and Aegerion Bankruptcy Case |
| 08/23/2019 |
SC 13G
| Stonepine Capital Management, LLC reports a 6.1% stake in Novelion Therapeutics Inc. |
| 08/21/2019 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events |
|